The adaptive, biomarker-directed trial allows researchers to enrich for best responders and open new sub-studies for non-responders based on emerging data.

Making clinical trials easier to find for clinicians and making protocols for entering clinical trials more lenient can help ...

Optical coherence tomography markers—like the ellipsoid zone—are reshaping clinical trials in intermediate age-related ...

OCCAM Immune, a Mount Sinai research organization, will sequence and map cells from samples collected in CRI's immunotherapy trials.

Xeris Biopharma Holdings is a company that has successfully launched products which are already generating revenue. Read why ...

MIRA Pharmaceuticals, Inc. (Nasdaq:MIRA) (”MIRA” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, ...

In a new collaboration that could transform how cancer is treated, OCCAM Immune-a Mount Sinai initiative focused on ...

The investigational treatment DZD8586 elicited encouraging antitumor activity with manageable toxicity in heavily pretreated ...

The researchers hypothesized that sildenafil would increase oxygen flow to the placenta and to the unborn fetus, reducing ...

While cancelled NIH grants and regulatory uncertainty are less hospitable to clinical research in the U.S., Europe must play ...

BIO International Convention (BIO2025), the world’s largest annual biotech event, will take place from June 16 to 19 (U.S.

How can early decisions in cell and gene therapy clinical development impact downstream progress toward commercialization and ...